Abstract: The invention concerns a compound of Formula (I) or a salt thereof, wherein R1 is H, (C1-C3)alkyl or CF3; R2 is H, (C1-C3)alkyl or CF3; A is CH2COOH, XCH2COOCH2CH3, XCH2COOH, XCH2CH2NH2, where X is nitrogen or oxygen atom; Ar is an aromatic fragment selected from the group consisting of (Ar1), (Ar2) and (Ar3); where R3 is H, —CH3, —CH2CH3 or CH3CO—, R4 is H or —CH3, R5 is H or —CH3, and R6 is H or —CH3. The compounds of Formula (I) can be used in the treatment of diseases modulated by thyroid hormone receptor-beta (TRb or TR?).

Abstract: The present invention concerns the field of neurodegenerative diseases, and in particular relates to compounds, pharmaceutical compositions and their uses in the protection of neuronal cells from inflammation and from oxidative stress in the early stage of Parkinson's Disease as well as in Alzheimer's Disease.

Abstract: The present invention relates to a pharmaceutical composition comprising: —an extract of Ajuga reptans comprising an amount of phenylpropanoids from 30% to 70% by weight with respect to the weight of the extract, wherein said amount of phenylpropanoids comprises an amount from 10 to 50% of teupolioside with respect to the total phenylpropanoid weight, and —an extract of Epilobium comprising an amount from 20 to 50% by weight of polyphenols with respect to the weight of the extract, wherein said amount of polyphenols comprises up to 3% by weight of oenothein B with respect to the total amount of polyphenols. Also described is the pharmaceutical composition of the invention for use in the treatment of prostatic diseases, in particular the benign prostatic hyperplasia.

Abstract: The present invention concern a 2-oxo-1,2-dihydropyridine-3-carboxamide compound of Formula (I) and new 2-oxo-1,2-dihydropyridine-3-carboxamide compounds of Formula (II) in the treatment of pathologies which require an inhibitor of PDK1 enzyme such as diabetes, neurodegenerative diseases such as Alzheimer's and Prion Diseases, and tumors such as breast, and pancreatic cancers and glioblastoma, particularly glioblastoma.

Abstract: The present invention concern a 2-oxo-1,2-dihydropyridine-3-carboxamide compound of Formula (I) in the treatment of pathologies which require a dual inhibitor of PDK1/AurA enzymes such as for instance tumours, particularly glioblastoma.

Abstract: The invention relates to a combination having antitumour activity, wherein an agent having antineoplastic activity, such as gemcitabine or temozolomide, is associated with an alkaloid of Chelidonium majus (C. majus), such as berberine, chelidonine or protopine.

Abstract: The present invention concern a 2-oxo-1,2-dihydropyridine-3-carboxamide compound of Formula (I) and new 2-oxo-1,2-dihydropyridine-3-carboxamide compounds of Formula (II) in the treatment of pathologies which require an inhibitor of PDK1 enzyme such as diabetes, neurodegenerative diseases such as Alzheimer's and Prion Diseases, and tumours such as breast, and pancreatic cancers and glioblastoma, particularly glioblastoma.

Abstract: A method and a system for transmitting data over a communication network (3). At least three computer systems (2, 5, 16) are connected to the communication network (3). A first message (7) is sent from the first computer system (2) to the second computer system (5). A second message is sent from the second computer system (5) to the third computer system (16). A third message is sent from the first computer system (2) to the third computer system (16). The third computer systems compares the contents of the second and third messages received from the first and second computer systems and verify the identities of the subjects who operates the first and second computer systems thus guarantying the identity of the subjects, the confidentiality of the data transmitted and the reliability of the transmission.